MARKET

EYEG

EYEG

EyeGate Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.85
-0.75
-9.87%
After Hours: 6.86 +0.01 +0.15% 16:00 01/17 EST
OPEN
7.66
PREV CLOSE
7.60
HIGH
7.66
LOW
6.81
VOLUME
175.10K
TURNOVER
--
52 WEEK HIGH
12.89
52 WEEK LOW
2.250
MARKET CAP
31.16M
P/E (TTM)
-2.7935
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EYEG and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EYEG News

  • EyeGate Pharma completes enrollment in follow-on study of ocular bandage gel
  • Seeking Alpha - Article.01/06 14:17
  • EyeGate Pharma Completes Enrollment in Follow-on PE Pilot Study
  • ACCESSWIRE.01/06 11:55
  • Aimmune's PDUFA Jitters, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article.01/05 13:08
  • EyeGate Announces Completion of $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
  • ACCESSWIRE.01/03 15:25

More

Industry

Pharmaceuticals
+0.13%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About EYEG

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
More

Webull offers Eyegate Pharmaceuticals Inc (EYEG) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.